Oric Pharmaceuticals, Inc.
ORIC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796280
In the last 90 days, Oric Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 5 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; Viking Global Investors is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:21 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 18, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating expenses | $143.0M | $142.9M | $110.8M | $91.8M | $78.9M |
| Research and development | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M |
| Selling, general and administrative | $33.2M | $28.8M | $25.6M | $25.1M | $22.0M |
| Operating income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M |
| EPS, basic | $-1.47 | $-1.83 | $-1.96 | $-2.25 | – |
| EPS, diluted | $-1.47 | $-1.83 | $-1.96 | $-2.25 | – |
| Weighted shares, basic | 87.8M | 69.7M | 51.5M | 39.7M | – |
| Weighted shares, diluted | 87.8M | 69.7M | 51.5M | 39.7M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 18, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $45.7M | $59.4M | $23.4M | $66.8M | $226.0M |
| Total current assets | $288.5M | $262.3M | $212.6M | $210.5M | $240.5M |
| Property, plant and equipment | $2.42M | $2.92M | $2.86M | $3.25M | $2.41M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M |
| Accounts payable | $3.82M | $1.55M | $944.0K | $1.32M | $1.89M |
| Total current liabilities | $20.4M | $24.8M | $20.5M | $15.4M | $15.2M |
| Long-term debt | – | – | – | – | $10.5M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M |
| Shareholders' equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 23, 2026 | Feb 18, 2025 | Jan 9, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$111.0M | -$112.7M | -$85.7M | -$75.1M | -$59.5M |
| Capital expenditures | $712.0K | $1.19M | $849.0K | $2.08M | $939.0K |
| Free cash flow | -$111.7M | -$113.8M | -$86.5M | -$77.2M | -$60.5M |
| Stock-based compensation | $25.0M | $20.2M | $15.2M | $14.5M | $12.9M |
| Investing cash flow | -$148.0M | $22.1M | -$43.4M | -$109.2M | $158.4M |
| Financing cash flow | $245.3M | $126.5M | $85.7M | $25.2M | $49.1M |
| Net change in cash | -$13.7M | $36.0M | -$43.4M | -$159.2M | $148.0M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 27, 2026 | 103.7M | +6.7% | SEC |
| Apr 27, 2026 | 103.5M | +45.6% | SEC |
| Feb 12, 2026 | 100.4M | +41.3% | SEC |
| Nov 5, 2025 | 97.4M | +38.0% | SEC |
| Aug 5, 2025 | 97.1M | +37.7% | SEC |
| Apr 28, 2025 | 71.1M | +5.4% | SEC |
| Feb 4, 2025 | 71.0M | +5.4% | SEC |
| Oct 31, 2024 | 70.6M | +29.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.